# Absolute Bioavailability and Nasopharyngeal Absorption of Intranasal Ketamine

> **NCT00520169** · PHASE1 · COMPLETED · sponsor: **Javelin Pharmaceuticals** · enrollment: 32 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** intranasal ketamine

## Key facts

- **NCT ID:** NCT00520169
- **Lead sponsor:** Javelin Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2007-09
- **Final completion:** 2007-09
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2008-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00520169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00520169, "Absolute Bioavailability and Nasopharyngeal Absorption of Intranasal Ketamine". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00520169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*